T F Dekoning

418 total citations
10 papers, 349 citations indexed

About

T F Dekoning is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, T F Dekoning has authored 10 papers receiving a total of 349 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 4 papers in Oncology and 3 papers in Cancer Research. Recurrent topics in T F Dekoning's work include Cancer therapeutics and mechanisms (5 papers), DNA Repair Mechanisms (3 papers) and Bioactive Compounds and Antitumor Agents (2 papers). T F Dekoning is often cited by papers focused on Cancer therapeutics and mechanisms (5 papers), DNA Repair Mechanisms (3 papers) and Bioactive Compounds and Antitumor Agents (2 papers). T F Dekoning collaborates with scholars based in United States and Norway. T F Dekoning's co-authors include J. Patrick McGovren, George L. Clarke, Robert C. Kelly, Tanya L. Wallace, Martha A. Warpehoski, Mark D. Prairie, William C. Krueger, Ilse Gebhard, Li H. Li and Guy E. Padbury and has published in prestigious journals such as Cancer Research, Journal of Medicinal Chemistry and Journal of Pharmaceutical Sciences.

In The Last Decade

T F Dekoning

10 papers receiving 330 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
T F Dekoning United States	8	262	134	84	62	61	10	349
James D. Liddil United States	12	253 1.0×	97 0.7×	86 1.0×	54 0.9×	26 0.4×	19	427
Ilse Gebhard United States	8	283 1.1×	200 1.5×	97 1.2×	59 1.0×	70 1.1×	8	400
J.A. Hartley United Kingdom	12	311 1.2×	155 1.2×	68 0.8×	76 1.2×	19 0.3×	22	424
K. MAEDA Japan	6	155 0.6×	132 1.0×	87 1.0×	24 0.4×	111 1.8×	12	357
Mithu Banerjee India	4	283 1.1×	237 1.8×	74 0.9×	34 0.5×	41 0.7×	4	503
Kathleen A. Salvato United States	7	159 0.6×	124 0.9×	123 1.5×	15 0.2×	88 1.4×	10	363
Elizabeth Altschuler United States	11	331 1.3×	81 0.6×	147 1.8×	60 1.0×	19 0.3×	17	391
Antoinette Wozniak United States	6	225 0.9×	47 0.4×	115 1.4×	18 0.3×	38 0.6×	7	357
R Bai United States	6	249 1.0×	187 1.4×	170 2.0×	15 0.2×	160 2.6×	10	523
Irina Chuckowree United Kingdom	9	289 1.1×	221 1.6×	206 2.5×	45 0.7×	21 0.3×	13	504

Countries citing papers authored by T F Dekoning

Since Specialization

Citations

This map shows the geographic impact of T F Dekoning's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by T F Dekoning with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites T F Dekoning more than expected).

Fields of papers citing papers by T F Dekoning

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by T F Dekoning. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by T F Dekoning. The network helps show where T F Dekoning may publish in the future.

Co-authorship network of co-authors of T F Dekoning

This figure shows the co-authorship network connecting the top 25 collaborators of T F Dekoning. A scholar is included among the top collaborators of T F Dekoning based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with T F Dekoning. T F Dekoning is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

Zhang, Yuwen, Yanli Su, Sharianne G. Louie, et al.. (2008). Combination efficacy with MetMAb and erlotinib in a NSCLC tumor model highlight therapeutic opportunities for c-Met inhibitors in combination with EGFR inhibitors. Cancer Research. 68. 1336–1336. 9 indexed citations

Kuo, Ming‐Shang, et al.. (1999). Isolation and identification of a major metabolite of PNU‐107859, an MMP inhibitor from the biliary fluid of rats. Journal of Pharmaceutical Sciences. 88(7). 705–708. 6 indexed citations

Johnson, Roy A., Paul J. Dobrowolski, Eldon G. Nidy, et al.. (1997). 12,13-Isotaxanes: Synthesis of New Potent Analogs and X-ray Crystallographic Confirmation of Structure. Journal of Medicinal Chemistry. 40(18). 2810–2812. 7 indexed citations

Carter, Charleata A., et al.. (1996). Preclinical antitumor activity of bizelesin in mice.. PubMed. 2(7). 1143–9. 18 indexed citations

Dekoning, T F, Robert C. Kelly, William C. Krueger, et al.. (1992). Cytotoxicity and antitumor activity of carzelesin, a prodrug cyclopropylpyrroloindole analogue.. PubMed. 52(18). 4904–13. 81 indexed citations

Li, Li H., Robert C. Kelly, Martha A. Warpehoski, et al.. (1991). Adozelesin, a selected lead among cyclopropylpyrroloindole analogs of the DNA-binding antibiotic, CC-1065. Investigational New Drugs. 9(2). 137–148. 66 indexed citations

Wallace, Tanya L., T F Dekoning, Martha A. Warpehoski, et al.. (1987). Structure and activity relationship of several novel CC-1065 analogs. Investigational New Drugs. 5(4). 329–337. 27 indexed citations

Li, L.H., T F Dekoning, & Tanya L. Wallace. (1987). Relationship between modulation of natural killer cell activity and antitumor activity of bropirimine when used in combination with various types of chemotherapeutic drugs.. PubMed. 47(22). 5894–900. 9 indexed citations

Wallace, Tanya L., et al.. (1987). Pharmacological evaluation of combination therapy of P388 leukemia with cyclophosphamide and pyrimidinones. International Journal of Immunopharmacology. 9(1). 31–39. 3 indexed citations

10.

McGovren, J. Patrick, et al.. (1984). Preliminary toxicity studies with the DNA-binding antibiotic, CC-1065.. The Journal of Antibiotics. 37(1). 63–70. 123 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact